Navenibart clinical trials
Also written STAR-0215.
How each study uses navenibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the navenibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test navenibart, phase 3 first.
- Dec 2026A Study of Navenibart in Participants With Hereditary AngioedemaPhase 3 · Astria Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses navenibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationPhase 3Astria Therapeutics, Inc.NCT07204938Written as navenibart
- A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingPhase 3Astria Therapeutics, Inc.NCT06842823Written as navenibart
- A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedPhase 1/2Astria Therapeutics, Inc.NCT05695248Written as Navenibart
- A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingPhase 2Astria Therapeutics, Inc.NCT06007677Written as STAR-0215
- A Study of STAR-0215 in Healthy Adult ParticipantsCompletedPhase 1Astria Therapeutics, Inc.NCT05477160Written as STAR-0215 (SC)
Codes
What other systems call navenibart · ClinicalTrials.gg INT015811
- UNII (FDA) 975UQE9GY6NAVENIBARTOne source FDA
- NCI Thesaurus C203148NavenibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 975UQE9GY6 | NAVENIBART | One source FDA |
| NCI Thesaurus | C203148 | Navenibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.